|
Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma. |
|
|
Honoraria - Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Novartis (Inst); Rgenix; Rgenix |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
Patents, Royalties, Other Intellectual Property - EpicentRx; RadioRx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
Employment - Cascade Medical Enterprises |
Stock and Other Ownership Interests - Becton Dickinson; Cascade Medical Enterprises |
Consulting or Advisory Role - Cascade Medical Enterprises |
|
|
Stock and Other Ownership Interests - Amgen; Immunogen; Teva |
|
|
Stock and Other Ownership Interests - Soligenix |
|
Christopher Andrew Barker |
Honoraria - Driver Group; Elsevier |
Consulting or Advisory Role - Patient Resource; Pfizer |
Speakers' Bureau - Omniprex |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Elekta (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Driver Group; Pfizer |